We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Offers Specific Treatment for Ovarian Cancer

By LabMedica International staff writers
Posted on 21 Sep 2014
Print article
Image: The multiplex biomarker immunoassay platform (Photo courtesy of Aushon BioSystems).
Image: The multiplex biomarker immunoassay platform (Photo courtesy of Aushon BioSystems).
A new blood test has been developed allowing doctors to predict which ovarian cancer patients will respond to particular types of treatment.

Ovarian cancer is the fourth most common cause of female cancer-related death, accounting for thousands of lives each year and for several decades the standard of care has been surgery and platinum-based cytotoxic chemotherapy.

Scientists at the University of Manchester (UK) and their colleagues collected blood samples from patients enrolled in an international trial of bevacizumab. These patients received the standard chemotherapy treatment alone or chemotherapy plus the blood vessel-targeting drug. This included blood samples from 91 pretreatment training and 114 validation patients. Plasma concentrations of 15 angio-associated factors were determined using validated multiplex enzyme-linked immunosorbent assays (ELISA).

The ELISAs were performed using the SearchLight Plus charged couple device imaging system (Aushon BioSystems; Billerica, MA, USA). Angiogenesis-associated protein concentrations were assessed using two six-plex ELISAs of angiopoietin-2 (Ang2) , fibroblast growth factor (FGFb), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGFbb), vascular endothelial growth factors (VEGFA and VEGFC) and granulocyte colony–stimulating factor (GCSF), interleukin, IL8 (IL8), keratinocyte growth factor (KGF), placental growth factor (PlGF), VEGF receptors (VEGFR1, and VEGFR2), respectively, a duplex of Ang1 and Tunica internal endothelial cell kinase 2 (Tie2) and a single plex of VEGFD.

Among women with high Ang1 and low Tie2 plasma concentrations, there was a greater chance of tumor response after bevacizumab treatment compared with standard treatment. Specifically, the effective predictor of a beneficial effect of bevacizumab was the combination of a supra-median concentration of Ang1 and an infra-median concentration of Tie2. The biomarker combination provides predictive information, over and beyond, that provided by the two markers individually. The biologic implication of these finding is that the Ang1–Tie2 axis may play a pivotal role in mediating resistance to VEGF pathway inhibitors. The authors concluded that that ovarian cancer, which is an angiogenesis-dependent disease, might be categorized into VEGF or Ang inhibitor–sensitive disease. The question remains of whether treatment with one inhibitor leads to escape through the alternate mechanism.

Gordon C. Jayson, FRCP, PhD, a Professor of Medical Oncology and senior author of the study, said, “We are keen to identify predictive biomarkers, measures that can indicate how well a patient will respond to treatment, so we can better target these drugs to patients most likely to benefit. We investigated levels of a range of proteins in patients' pretreatment blood samples to see if any were associated with improved survival.” The study was published on September 1, 2014, in the journal Clinical Cancer Research.

Related Links:

University of Manchester 
Aushon BioSystems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.